As banks navigate a landscape scarred by the Synapse bankruptcy, they need to build or buy the technical ability to reconcile accounts daily and vet any new fintech partners more thoroughly.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

Quisitive Technology Solutions, Inc. (CVE:QUIS – Get Free Report) has received an average recommendation of “Moderate Buy” ...

Shares of Quisitive Technology Solutions, Inc. (CVE:QUIS – Get Free Report) rose 46.7% during trading on Friday after Raymond James raised their price target on the stock from C$0.54 to C$0.57.

Quisitive Technology Solutions (CVE:QUIS – Get Free Report) was downgraded by stock analysts at Ventum Financial from a “buy” ...

The bankruptcy of banking-as-a-service startup Synapse Financial Technologies left thousands of fintech customers without ...

The recent failures of Synapse, Evolve, and Bench highlight the challenges of recent fintech innovations, which are often ...

Some gaming mice are specifically designed for certain game types, so it’s worth considering what titles you enjoy before ...

Depositors' funds were moved without authorized permission. but the terms of services say it's legal.